Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Panacea Biotec Ltd announces collaboration with Serum Institute of India Pvt. Ltd. and Bilthovan Biologicals B.V.

Posted On: 2018-01-18 00:31:35

Panacea Biotec Ltd. (PBL) is delighted to announce the collaboration with signing of two long term agreements with Serum Institute of India Pvt. Ltd. (511) and Sil's wholly owned subsidiary, Bilthovan Biologicals B.V. (BBIO). Under the collaboration 511 is entitled to manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwPHepB-Hib-IPV) developed & commercialized by Panacea Biotec, a first of its kind in this category.

Under the collaboration, broadly the following will be achieved:-

- Serum Institute of India will ensure supply of IPV bulk to Panacea Biotec, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in The Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the World.

- In next 2 years both SII and PBL will work together to get this wP-IPV based Hexavalent Vaccine introduced in the National Immunization Program of Government of India and developing countries by working closely with key stakeholders including but not limited to National Governments, World Health Organization (WHO), Global Alliance for Vaccines & Immunization (GAVI), Bill and Melinda Gates Foundation (BMGF) and other United Nation Agencies, etc.

Speaking on the occasion Dr Rajesh Jain, Joint Managing Director, Panacea Biotec said that millions of children in developing countries with an annual birth cohort of approx. 121 Million will get an easy access to a fully liquid Hexavalent vaccine containing six very important antigens to protect against six dreaded diseases i.e. Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type B & Polio. Dr. Rajesh Jain added that it is the first fully liquid wP-IPV based hexavalent vaccine in the World which Panacea Biotec has developed making India proud under Government of India's Make in India Program and currently being marketed in India under brand name EasySix™.

WHO prequalified IPV is essential to successfully eradicating Polio across the globe, an effort that has already cost $ 20 Billion worldwide. There is a Global Polio Eradication Initiative (GPEI) in place & Global Alliance for Vaccine Initiative (GAVI) has been supporting the program since 2013 having allocated $430 Million till 2018 with an additional donor pledge of $23 Million for 2019. At present GAVI is evaluating IPV under Vaccine Investment Strategy for Global Public Good.

Global demand of IPV/ IPV containing vaccines is estimated to rise significantly from ~100 Million in the year 2020 till supply constraints remain, to 250-350 Million doses every year starting 2022 depending upon a two or three dose schedule as Strategic Advisory Group of Experts (SAGE) on Immunization in April 2017 has recommended at least 2 doses of IPV in the routine Immunization schedule of the countries post OPV withdrawal.

Here it is important to note that there has been a global supply constraint of IPV since early 2015 and only 52% of projected supply had been delivered to UN agencies as a result of which 18 Countries could not introduce IPV in their immunization & 15 had interruptions out of 70 IPV eligible countries approved for GAVI support.

A beaming Mr Adar C. Poonawalla, CE.O. & Executive Director, Serum Institute of India, said, lilt is an historic deal where in two major vaccine Companies in India have come forward to join hands to address unmet needs of both Private & Public Market globally. With the convenience of 'Six in one' it has potential of over 250 million doses in next 3-4 years with a market size of over $1.25 Billion annually."

Mr R K Suri, Senior Advisor, who orchestrated the mega deal between two big Vaccine players said, lilt marks beginning of a new Era in vaccine landscape and heralds a new business model, 'Collaborate yet Compete!'."

Shares of PANACEA BIOTEC LTD. was last trading in BSE at Rs.256.9 as compared to the previous close of Rs. 253.7. The total number of shares traded during the day was 64132 in over 1624 trades.

The stock hit an intraday high of Rs. 264.15 and intraday low of 244.55. The net turnover during the day was Rs. 16561499.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Radhakishan Shivkishan Damani's Derive Investments buys Fortis Healthcare's shares
Indo Credit Capital Ltd calls for Board Meeting on Feb 26, 2018
Gilada Finance & Investments Ltd fixes Feb 28, 2018 as record date for dividend
Petron Engineering Construction Ltd announces resignation of 2 directors
Godawari Power and Ispat Ltd approves amalgamation of Jagdamba Power & Alloys Limited
JSW Energy enters into MoU with Maharashtra Government for Electric Vehicles plant
Chemcrux Enterprises Ltd calls for Board Meeting On February 27, 2018
ONGC Board to consider Second Interim Dividend on Feb 27, 2018
Advanced Enzyme Technologies Ltd approves additional investment in Malaysian subsidiary
Vascon Engineers Ltd signs agreement with Lina Ashar Foundation
Shilpa Medicare Ltd Board to consider Interim Dividend on Feb 22, 2018 opens its largest fulfillment center in Andhra Pradesh
Housing and Urban Development Corporation Ltd to consider interim dividend on Feb 28, 2018
Airtel and HMD Global partner to offer affordable 4G smartphones
Varun Beverages Ltd arm commences production at Zimbabwe plant
Infosys Recognised as a Top Employer in Europe
Pennar Industries Limited and its subsidiaries receive orders worth Rs. 152 crores
TRENT Ltd allots Commercial Paper for Rs. 100 crores
AXIS Bank fixes 1 year MCLR at 8.40% from Feb 17, 2018
Gayatri Projects announces reorganization of energy investments in arm
Himalaya Food International Ltd opens first QSK
Shree Cement Ltd commissions new grinding unit at Aurangabad in Bihar
Quadrant Televentures Limited calls for Board Meeting On February 23, 2018
CL Educate Ltd arm sells land for Rs. 6.48 crores
Pfizer Ltd announces resignation of CFO
Goodricke Group Ltd inducts additional director
Premier Explosives receives Management System Certificate from DNV GL Business Assurance, USA
Pod Solutions and Subex partner to provide advanced security for IoT Billing and Connectivity Service
Vikas WSP Ltd receives orders for Rs. 106.23 crores
Andhra Petrochemicals Ltd announces resumption of Plant operations from 19.2.2018
Glenmark Pharmaceuticals Presents New Data on GBR 830 at the 2018 American Academy of Dermatology Annual Meeting
L&T Construction Wins Orders Valued Rs. 1680 Crore
Indian Dairy Association honours Mr. RG Chandramogan with Patronship Award
Siemens Ltd to consider sale of mobility business, mechanical drives business
City Union Bank updates on cyber attack on its SWIFT payment system
Asian Granito India Ltd redeems commercial paper of Rs. 40 crores
Mawana Sugars Ltd calls for Board Meeting on Feb 20, 2018
UCO Bank's exposure at $411.82 million in PNB fraud
Religare Enterprises to raise up to Rs 1200 crore, inducts 3 new board members
RMC Switchgears Ltd to consider preferential issue, appoitnment
Indrayani Biotech Ltd appoints Mr. Kasiraman Sayee Sundar as additional director
Precision Wires India Ltd updates on increase in power charges by 20%
Mahindra Lifespaces - HDFC Capital affordable housing platform launches its first project
KPR Mill Ltd to consider buy back on Feb 22, 2018
Prime Focus Limited announces Q3 FY17-18 results
Varun Beverages Ltd. announces Q4 & CY2017 Financial Results CY2017
ITI Limited Announces Financial Results for the Quarter Ended December 31, 2017
ARSS Infrastructure Projects Ltd gets two work orders totaling Rs. 121.09 crores
Asian Oilfield Services Ltd announces resignation of CFO
PU Paint shop goes into commercial production

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018